Skip to main content
Premium Trial:

Request an Annual Quote

UCSF Licenses Heart Gene IP from Celera

NEW YORK (GenomeWeb News) – Celera said today that the University of California, San Francisco has licensed the rights to use Celera’s KIF6 gene-related intellectual property to develop an in-house test for cardiovascular risk and statin benefit.

The agreement makes UCSF the first lab in the US besides Celera’s Berkeley HeartLab subsidiary to use the Celera discoveries.

Studies have shown an association between KIF6, which encodes a kinesin-like protein 6, and cardiovascular risk and statin benefit.

Under the agreement, UCSF will be allowed to develop and perform a test using KIF6 for three years in California.

Celera CEO Kathy Ordonez said in a statement that the agreement is “consistent with Celera’s strategy to make KIF6 testing broadly available and our efforts to drive our new genetic discoveries into routine personalized care for patients with risk for cardiovascular disease."

Financial terms of the agreement were not released.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.